Ketamine vs. ECT: Effectiveness, Side Effects, and Speed

How Do Ketamine Therapy and ECT Compare for Depression?

Ketamine therapy and ECT are both effective for depression that has not responded to antidepressants, and for many people with nonpsychotic depression their results are broadly comparable. ECT holds a modest edge in the most severe cases, while ketamine works with less cognitive burden and no anesthesia. Here is how they line up, including the three ways ketamine is delivered.

How Does Electroconvulsive Therapy (ECT) Work for Depression?

Electroconvulsive therapy (ECT) treats depression by passing a brief, controlled electrical current through the brain to trigger a short, therapeutic seizure while you are under general anesthesia. Researchers believe that seizure activity helps reset mood-regulating circuits and prompts changes in neurotransmitter signaling and neuroplasticity, though the exact mechanism is still not fully understood.

A typical session takes only a few minutes:

• You receive general anesthesia and a muscle relaxant, so you are asleep and still throughout.
• Electrodes deliver a brief current that induces a seizure lasting roughly 30 to 60 seconds.
• You wake within 5 to 10 minutes and rest in recovery, then need someone to take you home.

A full course usually runs 6 to 12 sessions, given 2 to 3 times a week. Electrode placement matters: right unilateral placement tends to cause fewer memory effects, while bilateral placement can work faster or in more severe cases but carries a higher cognitive cost.

How Does Ketamine Therapy Work for Depression?

Ketamine therapy works in an entirely different way. Rather than inducing a seizure, it acts on glutamate, the brain's most abundant chemical messenger, by blocking NMDA receptors. This is believed to trigger a rapid increase in synaptic connections and neuroplasticity, essentially helping the brain rewire circuits involved in mood.

Ketamine is given at sub-anesthetic, clinician-determined doses through three main routes:

• At home, as sublingual tablets or self-administered injections within a clinician-supervised program.
• Intravenously (IV) in a clinic.
• As esketamine (Spravato), a nasal spray given in a certified clinic.

During dosing, many people feel a temporary sense of dissociation, a mild detachment from body or surroundings. In a supervised setting this is expected and, for many, part of the therapeutic experience. Racemic ketamine is prescribed off-label, a common and legal medical practice, while esketamine is FDA-approved for treatment-resistant depression.

Ketamine Therapy vs. ECT: Which Is More Effective for Depression?

For nonpsychotic treatment-resistant depression, ketamine therapy and ECT are about equally effective, with ECT holding a modest edge in the most severe cases. Effectiveness comes down to two numbers: response (at least a 50% drop in symptoms) and remission (symptoms largely gone).

Head-to-head trials point in both directions:

• ELEKT-D (Anand 2023), the largest trial: ketamine response 55.4% vs. ECT 41.2%. Ketamine was at least as effective.¹
• KetECT (Ekstrand 2022): the opposite result, with remission of 63% for ECT vs. 46% for ketamine.²
• Rhee 2022 meta-analysis (6 studies): ECT produced greater symptom reduction on average, mainly in more severe depression.³

These results look contradictory, but they line up once you account for how the trials were run. Both were open-label, so patients and clinicians knew which treatment was given, which can influence outcomes. The populations also differed: ELEKT-D studied only nonpsychotic depression, where ketamine performs well, while KetECT included severe, hospitalized patients, where ECT is strongest. Timing matters too, because ECT tends to pull ahead over a full course, so trials that measure earlier can make ketamine look relatively stronger (Nikolin 2026).⁴ The point is not that either treatment failed, but that the better choice depends on how severe the depression is and when you measure.

In the real world, ketamine's numbers are consistent across delivery routes:

• At-home ketamine: Mindbloom's published studies of more than 14,000 patients show about 56% response and 28% remission (Mathai 2024, n=11,441; Parks 2026, n=3,041).⁵⁻⁶
• IV ketamine: comparable at 53.6% response and 28.9% remission (McInnes 2022).⁷
• ECT: ~51% remission (SEAN registry, n=2,074), but measured on more lenient scales in more severely ill patients, so it is not a like-for-like comparison.⁸
• Esketamine (Spravato): the weaker route on remission (Bahji 2021).⁹

Individual results vary.

How Long Does Relief Last With Ketamine and ECT?

Some people reach remission and are able to stop treatment, but both ketamine therapy and ECT typically require some form of maintenance to hold their gains, and for many, effects fade over time without it (Jelovac 2013).¹⁰ In head-to-head trials, relapse rates are split, favoring ketamine in one and ECT in the other, so neither has a durability advantage.¹⁻²

Which Works Faster: Ketamine Therapy or ECT?

Neither is meaningfully faster than the other. Both ketamine and ECT act quickly, which sets them apart from standard antidepressants that can take four to six weeks.

• IV ketamine: an antidepressant effect within hours in clinical studies (Kryst 2020).¹¹
• Esketamine (Spravato): measurable improvement from about 24 hours (Popova 2019).¹²
• At-home ketamine: first assessed around two weeks, which reflects when it is measured, not necessarily when relief begins.
• ECT: improvement builds over the first one to two weeks of a course, and it can pull ahead in the most severe cases (Nikolin 2026).⁴

Because both work fast, speed is rarely the deciding factor between them. The bigger differences are in side effects, access, and fit.

Ketamine Therapy vs. ECT: Side Effects and Safety

A key difference for people choosing between the two is tolerability. Both are considered safe under medical supervision, but ECT carries a heavier side-effect burden, led by memory and cognitive effects and the demands of general anesthesia. Ketamine therapy's side effects are usually mild and short-lived.

ECT and Memory Loss

Memory loss is the most well-known side effect of ECT. It is real, and for most people it is temporary. Around the time of treatment, many experience confusion and trouble with memory, but objective testing shows the majority of cognitive functions return to baseline within about two weeks, and some improve beyond it (Semkovska 2010).¹³

The exception is autobiographical memory, the recall of personal life events. A minority of patients are left with lasting gaps: in one large study, about 12% had marked, persistent retrograde amnesia at six months, most often with older bilateral electrode placement (Sackeim 2007).¹⁴ Modern technique, using right unilateral placement and brief or ultrabrief pulses, lowers this risk but does not remove it entirely.

Other ECT Side Effects

Beyond memory, ECT carries the burden of the procedure itself:

• General anesthesia at every session, with a muscle relaxant and a recovery period, which adds its own risks.
• Common, short-lived effects after a session, including headache, muscle aches, nausea, and temporary confusion (Andrade 2016).¹⁵
• Serious medical complications are rare (Langan Martin 2025).¹⁶

Ketamine Therapy Side Effects

By comparison, ketamine therapy has a strong safety profile, with side effects that are mild and brief. During dosing, some people feel temporary dissociation and a short-lived rise in blood pressure, which typically settles within about two hours, and no anesthesia is involved. In Mindbloom's real-world programs, serious side effects are rare and very few people stop treatment because of them (Mathai 2024; Parks 2026).⁵⁻⁶

Who Is a Good Candidate for Ketamine Therapy vs. ECT?

The right choice depends on how severe the depression is, its specific features, and your access and preferences. In short, ECT is the stronger option for the most severe cases, while ketamine therapy fits many people with nonpsychotic depression who want a lower-burden treatment.

ECT is often the better choice for:

• Severe, psychotic, or catatonic depression. ECT is highly effective here and is recommended first by major treatment guidelines (VA/DoD 2022; CANMAT 2023).¹⁷⁻¹⁸ In psychotic depression, remission rates reach roughly 95% (Petrides 2001).¹⁹
• Acute situations that need rapid, closely supervised care, including severe suicidal crises.
• People already in an inpatient or hospital setting.

Ketamine therapy is often a good fit for:

• Nonpsychotic depression that has not responded to antidepressants.
• People who want to avoid general anesthesia and the memory risks that come with ECT.
• People who need at-home or lower-burden access.

One important point: psychotic depression is generally not treated with at-home ketamine. Many programs screen out psychotic features, and the controlled research on ketamine excludes psychotic depression, so ECT is the appropriate route in those cases.

Ketamine Therapy vs. ECT: Access, Setting, and Cost

Access and cost are where these treatments differ most in everyday life. ECT is the most demanding to undergo, while ketamine ranges from in-clinic infusions to fully at-home care.

ECT requires the most logistics:

• A hospital or clinic, with general anesthesia at every session.
• Roughly 6 to 12 sessions over several weeks, usually 2 to 3 times a week.
• Someone to drive you home each time, since you cannot drive after anesthesia. Patient and provider surveys cite the lack of an escort and transportation as leading barriers to getting ECT.²⁰
• Typically covered by insurance, though it can be expensive for those without coverage, where a full course can run roughly $15,000 to $25,000.

In-clinic ketamine (IV or Spravato) removes the anesthesia but keeps much of the in-person burden:

• Repeated clinic visits, monitoring during and after each session, and often an escort home.
• IV ketamine typically runs $400 to $800 or more per session and is usually paid out of pocket. Esketamine (Spravato) is FDA-approved and more often covered by insurance, but requires frequent early clinic visits.

At-home ketamine removes most of those barriers:

• Treatment happens at home with no travel, no anesthesia, and no escort. Mindbloom, for example, delivers this clinician-supervised at-home model at $165 to $215 per session for new clients, usually paid out of pocket.

How to Choose Between Ketamine Therapy and ECT

There is no single right answer. The best choice depends on how severe your depression is, your priorities around side effects and access, and a conversation with a clinician who knows your history.

A few general guides:

• Consider ECT if your depression is very severe, includes psychotic or catatonic features, or needs rapid, closely supervised care. It is the most established option in these situations.
• Consider ketamine therapy if you have nonpsychotic depression, want to avoid anesthesia and memory risk, or need treatment that fits into your life without hospital visits. If you are uninsured, at-home ketamine is also far more affordable than paying for a full ECT course out of pocket.
• Either can be a strong option for treatment-resistant depression that has not responded to antidepressants. Both work faster than standard medication, and both usually need maintenance to sustain results.

Whichever direction you lean, the decision is best made with a qualified clinician who can weigh your medical history, past treatments, and personal preferences.